All In Biotech

Free tool

FAERS Monitor: Zynlonta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761196 or its brand name (Zynlonta, Loncastuximab Tesirine-Lpyl). Reports on generic versions are filed under their own applications.

Reports

410

Serious

308

75% of reports

Hospitalization

110

Death reported

146

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death69
  • disease progression33
  • rash32
  • pleural effusion24
  • fatigue22
  • photosensitivity reaction21
  • neutropenia18
  • anaemia16
  • thrombocytopenia15
  • covid-1914
  • oedema14
  • off label use14
  • pneumonia14
  • diffuse large b-cell lymphoma13
  • oedema peripheral12

Reports by year received

View as table
YearReports
20171
20181
20191
202126
202284
202377
202462
202568
202690

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,749 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
diffuse large b-cell lymphomaSignal1386.750.81,016
photosensitivity reactionSignal2165.343.11,266
pleural effusionSignal2420.213.7421
disease progressionSignal3314.310.3397
oedemaSignal1413.27.9147
thrombocytopeniaSignal156.94.270
neutropeniaSignal186.84.384
oedema peripheralSignal125.12.935
anaemiaSignal164.32.738
deathSignal694.13.3166
covid-19Signal144.12.430
rashSignal323.82.764
pneumoniaSignal142.21.38
fatigue221.41.03
off label use140.80.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.